Cohort Studyhigh evidence
Buprenorphine-Naloxone vs Extended-Release Naltrexone Following Opioid Withdrawal Treatment.
JAMA network open·July 1, 2026·PMID 42446876
Why it mattersFor patients completing medically managed opioid withdrawal, choosing between buprenorphine-naloxone and extended-release naltrexone involves trade-offs. This study provides real-world evidence that buprenorphine-naloxone may offer greater protection against nonfatal overdose, a key outcome for clinicians managing opioid use disorder.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled